NCT00627887

Randomised Controlled Trial of Electroconvulsive Therapy (ECT) in Relapse Prevention of Depression

Randomised Controlled Trial of Electroconvulsive Therapy (ECT) With Pharmacotherapy or Pharmacotherapy Alone in Relapse Prevention of Depression

• Status: Completed
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 56 (actual)
• Sponsor: Örebro County Council · Other Government
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The purpose of the study is to determine if continuation electroconvulsive therapy (ECT) is safe and effective in relapse prevention of depression.

Detailed description

Randomized multicenter clinical trial with two parallel groups. Patients with major depression (unipolar or bipolar), who have remitted with electroconvulsive therapy (ECT) are eligible. All patients receive pharmacotherapy (venlafaxine target dose 300mg/day, and lithium target dose 0,5-0,8 mmol/L). The intervention is continuation unilateral ECT weekly for the first 6 weeks thereafter every 2 weeks for one year. Depressive relapse is the primary outcome measure.

Conditions

• Depressive Disorder, Major

Interventions

Type	Name	Description
PROCEDURE	Electroconvulsive therapy	unilateral briefpulse ECT weekly for the first 6 weeks thereafter every 2 weeks for a total of one year
DRUG	venlafaxine	extended release target dose of 300mg/day duration of one year
DRUG	Lithium	serum concentration 0,5-0,8 mmol/L, one year duration

Timeline

• Start date: 2008-01-01
• Primary completion: 2012-05-01
• Completion: 2012-05-01
• First posted: 2008-03-04
• Last updated: 2012-06-22

Locations

4 sites across 1 country: Sweden